Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers.

European journal of pharmacology - 28 Apr 2008

Verma Malkhey, Martin Hans-Joerg, Haq Wahajul, O'Connor Timothy R, Maser Edmund, Balendiran Ganesaratnam K

Abstract excerpt

AKR1B10 is an aldose reductase (AR) homologue overexpressed in liver cancer and various forms of that enzyme in carcinomas catalyze the reduction of anticancer drugs, potential cytostatic drug, and dl-glyceraldehyde but do not catalyze the reduction of glucose. Kinetic parameters for wild-type and C299S mutant AKR1B10 indicate that substitution of serine for cysteine at position 299 reduces the affinity of this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aldehyde Reductase
Share to Antibiotics, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzothiazoles

Share to Cysteine

Share to Daunorubicin

Share to Phthalazines

Share to Pyrimidines

Share to Serine

Source

Open in PubMed Open full text

Identifiers

PMID: 18325492
DOI: 10.1016/j.ejphar.2008.01.036
PMCID: PMC6193476

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers.PMID 18325492Read ↗

Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid.Semantic proximity Read ↗

Modulation of activity and inhibitor sensitivity of rabbit aldose reductase-like protein (AKR1B19) by oxidized glutathione and SH-reagents.Semantic proximity Read ↗

Assessment of the inhibitory potential of anabolic steroids towards human AKR1D1 by computational methods and in vitro evaluation.Semantic proximity Read ↗

A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors.Semantic proximity Read ↗

SDR enzymes oxidize specific lipidic alkynylcarbinols into cytotoxic protein-reactive speciesSemantic proximity Read ↗

Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation.Semantic proximity Read ↗

Human carbonyl reductase 1 participating in intestinal first-pass drug metabolism is inhibited by fatty acids and acyl-CoAs.Semantic proximity Read ↗

Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases.Semantic proximity Read ↗

Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.Semantic proximity Read ↗

Phenanthridin-6-one derivatives as the first class of non-steroidal pharmacological chaperones for Niemann-Pick disease type C1 protein.Semantic proximity Read ↗

Structure-based design of a FAAH variant that discriminates between the N-acyl ethanolamine and taurine families of signaling lipids.Semantic proximity Read ↗

Selective Inhibitors of Aldo-Keto Reductases AKR1C1 and AKR1C3 Discovered by Virtual Screening of a Fragment LibrarySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.